You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches
Pulmonology
On demand events

ERS 2024 | Targeting IL-33 in COPD: Exploring New Frontiers for COPD Management

Professors Klaus Rabe, Paola Rogliani, and Dr. Stephanie Christenson explore the complexity of inflammatory pathways and phenotypes in COPD. They provide insights into the genetic association of IL-33 with COPD, and discuss preclinical findings.

Klaus Rabe
Stephanie Christenson
Paola Rogliani
MD, PhD, FERS
Klaus Rabe +2 more

On demand materials

ERS 2024 | Understanding the Complex Pathophysiology of COPD
Pulmonology
expert video

ERS 2024 | Understanding the Complex Pathophysiology of COPD

Learning objectives

  • Discuss the complexity of inflammatory pathways in COPD and different phenotypes
  • Provide evidence on the genetic association of IL-33 and COPD and early preclinical results
  • Discuss outcomes of IL-33 targeting and review the ongoing research in the science behind IL-33 in COPD, including its impact on airway remodeling and disease progression
Tags
symposium
MAT-US-2411585 v1.0 -P Exp Date: 10/28/2026

About these experts

Pulmonology
MD, PhD, FERS

Klaus Rabe

Professor of Pulmonary Medicine | University of Kiel; Director of the Department of Pneumology | LungClinic Grosshansdorf, Kiel, Germany

Pulmonology
MD, MAS

Stephanie Christenson

Associate Professor at the University of California, San Francisco in the Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine

Pulmonology
MD

Paola Rogliani

Professor, University of Rome 'Tor Vergata, Rome, Italy

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

Sanofi | Regeneron Logo

© 2024 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-US-2305040 v3.0-P Exp. Date: 11/24/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region